Cite
Preclinical evaluation of dual action intranasal formulation intended for postoperative/cancer associated therapies.
MLA
El-Setouhy, Doaa Ahmed, et al. “Preclinical Evaluation of Dual Action Intranasal Formulation Intended for Postoperative/Cancer Associated Therapies.” European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, vol. 76, Aug. 2015, pp. 48–56. EBSCOhost, https://doi.org/10.1016/j.ejps.2015.04.015.
APA
El-Setouhy, D. A., Ahmed, S., Badawi, A. A. E.-L., El-Nabarawi, M. A., & Sallam, N. (2015). Preclinical evaluation of dual action intranasal formulation intended for postoperative/cancer associated therapies. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 76, 48–56. https://doi.org/10.1016/j.ejps.2015.04.015
Chicago
El-Setouhy, Doaa Ahmed, Sami Ahmed, Alia Abd El-Latif Badawi, Mohamed Ahmed El-Nabarawi, and Nada Sallam. 2015. “Preclinical Evaluation of Dual Action Intranasal Formulation Intended for Postoperative/Cancer Associated Therapies.” European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences 76 (August): 48–56. doi:10.1016/j.ejps.2015.04.015.